Novo Nordisk A/S: Hemostatic Disorders trials

The registry lists 104 Hemostatic Disorders studies with Novo Nordisk A/S as lead sponsor. 0 are open to participants now and 26 have results posted.

Phase 1 32Phase 2 20Phase 3 21Phase 4 4No phase 27(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia ACompletedNCT03528551Phase 3Results posted
• Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks PeriodCompletedNCT03449342Phase 4Results posted
• A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With InhibitorsCompletedNCT03196284Phase 2Results posted
• Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia ACompletedNCT02938585Phase 3Results posted
• Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 TrialCompletedNCT02541942Phase 2Results posted
• A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia ACompletedNCT01731600Phase 3Results posted
• Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia ACompletedNCT01493778Phase 3Results posted
• Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.CompletedNCT01489111Phase 3Results posted
• Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia ACompletedNCT01480180Phase 3Results posted
• Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773CompletedNCT01395810Phase 3Results posted
• Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and InhibitorsCompletedNCT01392547Phase 3Results posted
• Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia BCompletedNCT01386528Phase 3Results posted
• Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B PatientsCompletedNCT01333111Phase 3Results posted
• Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit DeficiencyCompletedNCT01253811Phase 3Results posted
• Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit DeficiencyCompletedNCT01230021Phase 3Results posted
• Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia ACompletedNCT01138501Phase 3Results posted
• Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015CompletedNCT00984126Phase 3Results posted
• Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725CompletedNCT00978380Phase 3Results posted
• Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart SurgeryCompletedNCT00914589Phase 2Results posted
• PROPACT: Retrospective Prophylaxis Patient Case CollectionCompletedNCT00882778Results posted
• Safety and Efficacy of Turoctocog Alfa in Haemophilia A SubjectsCompletedNCT00840086Phase 3Results posted
• Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy VolunteersCompletedNCT00822185Phase 1Results posted
• Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited DeficiencyCompletedNCT00713648Phase 3Results posted
• Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With InhibitorsCompletedNCT00703911Results posted
• Haemophilia Patients With Inhibitors Being Treated for Acute Joint BleedsCompletedNCT00486278Phase 2Results posted
• Evaluation of Recombinant Factor VIIa in Patients With Severe BleedingTerminatedNCT00184548Phase 3Results posted
• Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A PatientsCompletedNCT03179748
• A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia BCompletedNCT03075670Phase 1
• Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia ACompletedNCT02994407Phase 1
• Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia ACompletedNCT02941354Phase 1
• A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia ACompletedNCT02920398Phase 1
• Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)CompletedNCT02568202
• To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily LivesCompletedNCT02241694
• Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary BypassCompletedNCT02239146Phase 1
• To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in JapanCompletedNCT02207218
• Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male SubjectsWithdrawnNCT02084810Phase 1
• Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia ACompletedNCT02035384
• Impact of Pain on Functional Impairment and Quality of Life in Adults With HemophiliaCompletedNCT01988532
• Project to Update the Study of Congenital Haemophilia in SpainCompletedNCT01959555
• A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without InhibitorsCompletedNCT01949792Phase 1
• A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in JapanCompletedNCT01876745
• Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational StudyCompletedNCT01862367
• Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy VolunteersCompletedNCT01848002Phase 1
• Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy VolunteersCompletedNCT01847989Phase 1
• A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With InhibitorsCompletedNCT01830712
• Treatment of Congenital Factor VII DeficiencyCompletedNCT01779921
• Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia ACompletedNCT01692925Phase 1
• A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia SubjectsTerminatedNCT01631942Phase 1
• Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic FeverCompletedNCT01601613Phase 2
• Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture ReconstructionCompletedNCT01601457Phase 2
• Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With InhibitorsCompletedNCT01586936
• Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing SurgeryCompletedNCT01579968
• Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical PracticeCompletedNCT01579955
• Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral HaemorrhageCompletedNCT01566786Phase 2
• Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell TransplantationTerminatedNCT01564563Phase 2
• Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma PatientsCompletedNCT01563523Phase 2
• Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy VolunteersCompletedNCT01563471Phase 1
• Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver TransplantationCompletedNCT01563458Phase 2
• Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral HaemorrhageCompletedNCT01563445Phase 2
• Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial HepatectomyCompletedNCT01562821Phase 2
• Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding StateCompletedNCT01562587Phase 1
• Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart DiseaseCompletedNCT01562574Phase 3
• Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding StateCompletedNCT01562457Phase 1
• Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell TransplantationCompletedNCT01562158Phase 2
• Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of ThromboelastographyCompletedNCT01561924Phase 1
• Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male SubjectsCompletedNCT01561417Phase 1
• Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCompletedNCT01561391Phase 4
• Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese SubjectsCompletedNCT01555749Phase 1
• Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing CountriesCompletedNCT01503567
• Observational Registry of the Treatment of Glanzmann's ThrombastheniaCompletedNCT01476423
• A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia ACompletedNCT01365520Phase 1
• Survey Evaluating the Psychosocial Effects of Living With HaemophiliaCompletedNCT01322620
• Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII DeficiencyCompletedNCT01312636
• Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B PatientsCompletedNCT01288391Phase 1
• Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired HaemophiliaCompletedNCT01285089
• Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male SubjectsCompletedNCT01272206Phase 1
• A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543CompletedNCT01238367Phase 1
• Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and InhibitorsCompletedNCT01234545
• Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or BCompletedNCT01228669Phase 1
• Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or BCompletedNCT01220141
• Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia ACompletedNCT01205724Phase 1
• Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese VolunteersCompletedNCT01153997Phase 1
• Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male SubjectsCompletedNCT01082406Phase 1
• Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia BCompletedNCT00956345Phase 1
• A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male VolunteersCompletedNCT00951873Phase 1
• Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With InhibitorsCompletedNCT00951405Phase 2
• Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and BCompletedNCT00922792Phase 1
• Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia DatabaseCompletedNCT00853086
• Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A SubjectsCompletedNCT00837356Phase 1
• Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IXCompletedNCT00710619
• Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in GermanyCompletedNCT00697320
• High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With InhibitorsCompletedNCT00571584Phase 4
• Recombinant Factor VIIa in Acute Intracerebral HaemorrhageCompletedNCT00426803Phase 2
• Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to TraumaWithdrawnNCT00323570Phase 3
• Factor VIIa in Acute Intracerebral HaemorrhageCompletedNCT00266006Phase 2
• Use of NovoSeven® in Active Variceal BleedingCompletedNCT00154492Phase 2
• Use of Activated Recombinant Human Factor VII in Cardiac SurgeryTerminatedNCT00154427Phase 2
• Recombinant Factor VIIa in Acute Intracerebral HaemorrhageCompletedNCT00127283Phase 3
• Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain InjuryCompletedNCT00124293
• Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain InjuryCompletedNCT00123591Phase 2